3. Verstovsek S, Mascarenhas J, Kremyanskaya M, et al. CPI-0610, Bromodomain and Extraterminal
Domain Protein (BET) Inhibitor, as "add-on" to Ruxolitinib, in advanced myelofibrosis patients with
suboptimal response: Update of MANIFEST Phase 2 study. 62nd ASH Annual Meeting and
Exposition. December 5, 2020. https://ash.confex.com/ash/2020/webprogram/Paper140891.html
4. Mascarenhas J, Harrison C, Patriarca A, et al. CPI-0610, a Bromodomain and Extraterminal Domain
Protein (BET) inhibitor, in combination with ruxolitinib, in JAK inhibitor treatment naïve
myelofibrosis patients: Update from MANIFEST phase 2 study. 62nd ASH Annual Meeting and
Exposition. December 5, 2020. https://ash.confex.com/ash/2020/webprogram/Paper139000.html
5. Mascarenhas J, Harrison C, Luptakova K, et al. MANIFEST-2, a global, Phase 3, randomized, double-blind,
active-control study of CPI-0610 and ruxolitinib vs. placebo and ruxolitinib in JAK-inhibitor-naïve
myelofibrosis patients. Blood 2020;136(Suppl. 1):43.
6. Rampal R, Ahn J, Abdel-Wahab O, et al. Genomic and functional analysis of leukemic transformation
of myeloproliferative neoplasms. Proc Natl Acad Sci. USA 2014;111:E5401–E5410.
7. Bose P, Verstovsek S, Cortes JE, et al. A phase 1/2 study of ruxolitinib and decitabine in patients
with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020;34(9):2489-2492.
8. Rampal RK, Mascarenhas JO, Kosiorek HE, Berenzon D, Hexner E, Abboud CN, et al. Safety and
efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative
neoplasms. Blood Adv. 2018;2(24):3572–3580.
9. Mascarenhas JO, Rampal RK, Kosiorek HE, et al. Phase 2 study of ruxolitinib and decitabine in
patients with myeloproliferative neoplasm in accelerated and blast phase. Blood Adv.
2020;4(20):5246-5256.
10. McKenney AS, Allison NL, Hanasoge Somasundra AV, Spitzer B, Intlekofer AM, et al. JAK2/IDH-mutant–
driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. J Clin
Invest. 2018;128(2):789–804.
11. Chifotides HT, Masarova L, Alfayez M, Daver N, Alvarado Y, Jabbour E, et al. Outcome of patients
with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood
Adv. 2020;4(21):5336-5342.
12. Bhagwat N, Koppikar P, Keller M, et al. Improved targeting of JAK2 leads to increased therapeutic
efficacy in myeloproliferative neoplasms. Blood. 2014;123(13):2075-83.
13. Pemmaraju N, Gundabolu K, Pettit K, et al. Phase 1b Study of the epichaperome inhibitor PU-H71
administered orally with ruxolitinib continuation for the treatment of patients with myelofibrosis.
Blood 2019;134(Suppl. 1):4178.
14. Petiti J, Lo lacono M, Rosso V, et al. Bcl-xL represents a therapeutic target in Philadelphia negative
myeloproliferative neoplasms. J. Cell Mol Med. 2020;24:10978-10986.
15. Pemmaraju N, Garcia JS, Potluri J, et al. The addition of navitoclax to ruxolitinib demonstrates
efficacy within different high-risk populations in patients with relapsed/refractory myelofibrosis.
Blood 2020;136(Suppl. 1):49-50.
16. Mascarenhas J, Vannucchi AM, Mead AJ, et al. An open-label, global, multicenter phase 1b/2 study
of KRT-232, a first-in-class, oral small-molecule inhibitor of murine double minute 2 (MDM2),
combined with ruxolitinib in patients who have myelofibrosis and a suboptimal response to
ruxolitinib. Blood 2020;136(Suppl. 1):44-45
17. Gerds AT, Vannucchi AM, Passamonti F, et al. Duration of response to Luspatercept in patients (Pts)
requiring red blood cell (RBC) transfusions with myelofibrosis (MF) – Updated data from the phase
2 ACE-536-MF-001 study. Blood 2020;136(Suppl. 1):47-48.